BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 29624883)

  • 1. Diagnosis and management of ADA2 deficient polyarteritis nodosa.
    Human A; Pagnoux C
    Int J Rheum Dis; 2019 Jan; 22 Suppl 1():69-77. PubMed ID: 29624883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment.
    Meyts I; Aksentijevich I
    J Clin Immunol; 2018 Jul; 38(5):569-578. PubMed ID: 29951947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2.
    Özen S; Batu ED; Taşkıran EZ; Özkara HA; Ünal Ş; Güleray N; Erden A; Karadağ Ö; Gümrük F; Çetin M; Sönmez HE; Bilginer Y; Ayvaz DÇ; Tezcan I
    J Rheumatol; 2020 Jan; 47(1):117-125. PubMed ID: 31043544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders.
    Hashem H; Kelly SJ; Ganson NJ; Hershfield MS
    Curr Rheumatol Rep; 2017 Oct; 19(11):70. PubMed ID: 28983775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study.
    Caorsi R; Penco F; Grossi A; Insalaco A; Omenetti A; Alessio M; Conti G; Marchetti F; Picco P; Tommasini A; Martino S; Malattia C; Gallizzi R; Podda RA; Salis A; Falcini F; Schena F; Garbarino F; Morreale A; Pardeo M; Ventrici C; Passarelli C; Zhou Q; Severino M; Gandolfo C; Damonte G; Martini A; Ravelli A; Aksentijevich I; Ceccherini I; Gattorno M
    Ann Rheum Dis; 2017 Oct; 76(10):1648-1656. PubMed ID: 28522451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis.
    Gibson KM; Morishita KA; Dancey P; Moorehead P; Drögemöller B; Han X; Graham J; Hancock REW; Foell D; Benseler S; Luqmani R; Yeung RSM; Shenoi S; Bohm M; Rosenberg AM; Ross CJ; Cabral DA; Brown KL;
    Arthritis Rheumatol; 2019 Oct; 71(10):1747-1755. PubMed ID: 31008556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monogenic polyarteritis: the lesson of ADA2 deficiency.
    Caorsi R; Penco F; Schena F; Gattorno M
    Pediatr Rheumatol Online J; 2016 Sep; 14(1):51. PubMed ID: 27609179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deficiency of adenosine deaminase 2 (DADA2): Review.
    Sharma V; Deo P; Sharma A
    Best Pract Res Clin Rheumatol; 2023 Mar; 37(1):101844. PubMed ID: 37328410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanding spectrum of DADA2: a review of phenotypes, genetics, pathogenesis and treatment.
    Pinto B; Deo P; Sharma S; Syal A; Sharma A
    Clin Rheumatol; 2021 Oct; 40(10):3883-3896. PubMed ID: 33791889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 9.5-year-old boy with recurrent neurological manifestations and severe hypertension, treated initially for polyarteritis nodosa, was subsequently diagnosed with adenosine deaminase type 2 deficiency (DADA2) which responded to anti-TNF-α.
    Sahin S; Adrovic A; Barut K; Baran S; Tahir Turanli E; Canpolat N; Kizilkilic O; Ozkaya O; Kasapcopur O
    Paediatr Int Child Health; 2020 Feb; 40(1):65-68. PubMed ID: 30642227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early-onset stroke and vasculopathy associated with mutations in ADA2.
    Zhou Q; Yang D; Ombrello AK; Zavialov AV; Toro C; Zavialov AV; Stone DL; Chae JJ; Rosenzweig SD; Bishop K; Barron KS; Kuehn HS; Hoffmann P; Negro A; Tsai WL; Cowen EW; Pei W; Milner JD; Silvin C; Heller T; Chin DT; Patronas NJ; Barber JS; Lee CC; Wood GM; Ling A; Kelly SJ; Kleiner DE; Mullikin JC; Ganson NJ; Kong HH; Hambleton S; Candotti F; Quezado MM; Calvo KR; Alao H; Barham BK; Jones A; Meschia JF; Worrall BB; Kasner SE; Rich SS; Goldbach-Mansky R; Abinun M; Chalom E; Gotte AC; Punaro M; Pascual V; Verbsky JW; Torgerson TR; Singer NG; Gershon TR; Ozen S; Karadag O; Fleisher TA; Remmers EF; Burgess SM; Moir SL; Gadina M; Sood R; Hershfield MS; Boehm M; Kastner DL; Aksentijevich I
    N Engl J Med; 2014 Mar; 370(10):911-20. PubMed ID: 24552284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficiency of Adenosine Deaminase 2: Clinical Manifestations, Diagnosis, and Treatment.
    Grim A; Veiga KR; Saad N
    Rheum Dis Clin North Am; 2023 Nov; 49(4):773-787. PubMed ID: 37821195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy.
    Garg N; Kasapcopur O; Foster J; Barut K; Tekin A; Kızılkılıç O; Tekin M
    Eur J Pediatr; 2014 Jun; 173(6):827-30. PubMed ID: 24737293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two cases of ADA2 deficiency presenting as childhood polyarteritis nodosa: novel ADA2 variant, atypical CNS manifestations, and literature review.
    Ganhão S; Loureiro GB; Oliveira DR; Dos-Reis-Maia R; Aguiar F; Quental R; Moura C; Barreira JL; Rodrigues M; Brito I
    Clin Rheumatol; 2020 Dec; 39(12):3853-3860. PubMed ID: 32535845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dermatologic Features of ADA2 Deficiency in Cutaneous Polyarteritis Nodosa.
    Gonzalez Santiago TM; Zavialov A; Saarela J; Seppanen M; Reed AM; Abraham RS; Gibson LE
    JAMA Dermatol; 2015 Nov; 151(11):1230-4. PubMed ID: 26131734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case with febrile attacks and vasculopathy associated with ADA2 and MEFV pathogenic variants.
    Parlar K; Tahir Turanli E; Nuhoglu Kantarci E; Hacioglu A; Kirectepe Aydin A; Ayla AY; Voyvoda U; Ozdogan H; Ugurlu S
    Mod Rheumatol Case Rep; 2023 Dec; 8(1):121-124. PubMed ID: 37542433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2.
    Schnappauf O; Sampaio Moura N; Aksentijevich I; Stoffels M; Ombrello AK; Hoffmann P; Barron K; Remmers EF; Hershfield M; Kelly SJ; ; Cuthbertson D; Carette S; Chung SA; Forbess L; Khalidi NA; Koening CL; Langford CA; McAlear CA; Monach PA; Moreland L; Pagnoux C; Seo P; Springer JM; Sreih AG; Warrington KJ; Ytterberg SR; Kastner DL; Grayson PC; Merkel PA;
    Arthritis Rheumatol; 2021 Mar; 73(3):512-519. PubMed ID: 33021335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histiocytoid Sweet Syndrome Presenting in Two Sisters With Deficiency of Deaminase Type 2.
    Hui Ong EL; Cooray S; Brogan P; Calonje E
    Am J Dermatopathol; 2023 Jan; 45(1):47-50. PubMed ID: 36484606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical phenotype of an old disease or typical phenotype of a new disease: deficiency of adenosine deaminase 2.
    Çakan M; Aktay-Ayaz N; Karadağ ŞG; Tahir-Turanlı E; Stafstrom K; Bainter W; Geha RS; Chou J
    Turk J Pediatr; 2019; 61(3):413-417. PubMed ID: 31916720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human adenosine deaminase 2 deficiency: A multi-faceted inborn error of immunity.
    Moens L; Hershfield M; Arts K; Aksentijevich I; Meyts I
    Immunol Rev; 2019 Jan; 287(1):62-72. PubMed ID: 30565235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.